Oral tranexamic acid for the treatment of melasma: evidence and experience-based consensus statement from Indian experts
Melasma, a chronic pigmentary skin condition mainly affecting the face, remains a challenge despite the availability of several options for treatment. Many melasma patients are not satisfied with treatment outcomes. Tranexamic acid (TXA), an anti-fibrinolytic drug has shown promising results in pati...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2023-01-01
|
| Series: | Indian Journal of Dermatology |
| Subjects: | |
| Online Access: | http://www.e-ijd.org/article.asp?issn=0019-5154;year=2023;volume=68;issue=2;spage=178;epage=185;aulast=Godse |
| _version_ | 1797824309941501952 |
|---|---|
| author | Kiran Godse Rashmi Sarkar Venkataram Mysore Manunath M Shenoy Manas Chatterjee Rajetha Damisetty Swapnil Shah Maya Vedamurthy Sanjeev Aurangabadkar Chakravarthi Srinivas Anil Ganjoo Sudip Das Anant Patil |
| author_facet | Kiran Godse Rashmi Sarkar Venkataram Mysore Manunath M Shenoy Manas Chatterjee Rajetha Damisetty Swapnil Shah Maya Vedamurthy Sanjeev Aurangabadkar Chakravarthi Srinivas Anil Ganjoo Sudip Das Anant Patil |
| author_sort | Kiran Godse |
| collection | DOAJ |
| description | Melasma, a chronic pigmentary skin condition mainly affecting the face, remains a challenge despite the availability of several options for treatment. Many melasma patients are not satisfied with treatment outcomes. Tranexamic acid (TXA), an anti-fibrinolytic drug has shown promising results in patients with melasma. Evidence from several clinical studies has surfaced on efficacy and tolerability of TXA in these patients. It can be used as monotherapy or adjuvant with other therapies. Currently, there is no published consensus or guideline document for its use in the treatment of melasma. TXA is available for oral use, topical use as well as an injection. In this article, a consensus of Indian experts is prepared based on the available literature and experience with use of oral TXA in melasma. This review article might help clinicians for use of oral TXA appropriately while treating melasma. |
| first_indexed | 2024-03-13T10:37:06Z |
| format | Article |
| id | doaj.art-757d4a6817994631a694972390c7e4bb |
| institution | Directory Open Access Journal |
| issn | 0019-5154 1998-3611 |
| language | English |
| last_indexed | 2024-03-13T10:37:06Z |
| publishDate | 2023-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Indian Journal of Dermatology |
| spelling | doaj.art-757d4a6817994631a694972390c7e4bb2023-05-18T05:46:28ZengWolters Kluwer Medknow PublicationsIndian Journal of Dermatology0019-51541998-36112023-01-0168217818510.4103/ijd.ijd_266_22Oral tranexamic acid for the treatment of melasma: evidence and experience-based consensus statement from Indian expertsKiran GodseRashmi SarkarVenkataram MysoreManunath M ShenoyManas ChatterjeeRajetha DamisettySwapnil ShahMaya VedamurthySanjeev AurangabadkarChakravarthi SrinivasAnil GanjooSudip DasAnant PatilMelasma, a chronic pigmentary skin condition mainly affecting the face, remains a challenge despite the availability of several options for treatment. Many melasma patients are not satisfied with treatment outcomes. Tranexamic acid (TXA), an anti-fibrinolytic drug has shown promising results in patients with melasma. Evidence from several clinical studies has surfaced on efficacy and tolerability of TXA in these patients. It can be used as monotherapy or adjuvant with other therapies. Currently, there is no published consensus or guideline document for its use in the treatment of melasma. TXA is available for oral use, topical use as well as an injection. In this article, a consensus of Indian experts is prepared based on the available literature and experience with use of oral TXA in melasma. This review article might help clinicians for use of oral TXA appropriately while treating melasma.http://www.e-ijd.org/article.asp?issn=0019-5154;year=2023;volume=68;issue=2;spage=178;epage=185;aulast=Godseadverse eventanti-fibrinolytic agentevidencetreatment outcome |
| spellingShingle | Kiran Godse Rashmi Sarkar Venkataram Mysore Manunath M Shenoy Manas Chatterjee Rajetha Damisetty Swapnil Shah Maya Vedamurthy Sanjeev Aurangabadkar Chakravarthi Srinivas Anil Ganjoo Sudip Das Anant Patil Oral tranexamic acid for the treatment of melasma: evidence and experience-based consensus statement from Indian experts Indian Journal of Dermatology adverse event anti-fibrinolytic agent evidence treatment outcome |
| title | Oral tranexamic acid for the treatment of melasma: evidence and experience-based consensus statement from Indian experts |
| title_full | Oral tranexamic acid for the treatment of melasma: evidence and experience-based consensus statement from Indian experts |
| title_fullStr | Oral tranexamic acid for the treatment of melasma: evidence and experience-based consensus statement from Indian experts |
| title_full_unstemmed | Oral tranexamic acid for the treatment of melasma: evidence and experience-based consensus statement from Indian experts |
| title_short | Oral tranexamic acid for the treatment of melasma: evidence and experience-based consensus statement from Indian experts |
| title_sort | oral tranexamic acid for the treatment of melasma evidence and experience based consensus statement from indian experts |
| topic | adverse event anti-fibrinolytic agent evidence treatment outcome |
| url | http://www.e-ijd.org/article.asp?issn=0019-5154;year=2023;volume=68;issue=2;spage=178;epage=185;aulast=Godse |
| work_keys_str_mv | AT kirangodse oraltranexamicacidforthetreatmentofmelasmaevidenceandexperiencebasedconsensusstatementfromindianexperts AT rashmisarkar oraltranexamicacidforthetreatmentofmelasmaevidenceandexperiencebasedconsensusstatementfromindianexperts AT venkatarammysore oraltranexamicacidforthetreatmentofmelasmaevidenceandexperiencebasedconsensusstatementfromindianexperts AT manunathmshenoy oraltranexamicacidforthetreatmentofmelasmaevidenceandexperiencebasedconsensusstatementfromindianexperts AT manaschatterjee oraltranexamicacidforthetreatmentofmelasmaevidenceandexperiencebasedconsensusstatementfromindianexperts AT rajethadamisetty oraltranexamicacidforthetreatmentofmelasmaevidenceandexperiencebasedconsensusstatementfromindianexperts AT swapnilshah oraltranexamicacidforthetreatmentofmelasmaevidenceandexperiencebasedconsensusstatementfromindianexperts AT mayavedamurthy oraltranexamicacidforthetreatmentofmelasmaevidenceandexperiencebasedconsensusstatementfromindianexperts AT sanjeevaurangabadkar oraltranexamicacidforthetreatmentofmelasmaevidenceandexperiencebasedconsensusstatementfromindianexperts AT chakravarthisrinivas oraltranexamicacidforthetreatmentofmelasmaevidenceandexperiencebasedconsensusstatementfromindianexperts AT anilganjoo oraltranexamicacidforthetreatmentofmelasmaevidenceandexperiencebasedconsensusstatementfromindianexperts AT sudipdas oraltranexamicacidforthetreatmentofmelasmaevidenceandexperiencebasedconsensusstatementfromindianexperts AT anantpatil oraltranexamicacidforthetreatmentofmelasmaevidenceandexperiencebasedconsensusstatementfromindianexperts |